Skip to main content

Advertisement

SpringerLink
Log in

Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim of this study is to explore the role of plasminogen activator inhibitor type 1 (PAI-1) in primary and secondary antiphospholipid syndrome (APS). Thirty patients of APS (24 primary and 6 secondary) were recruited in the study who fulfilled the revised Sapporo criteria. Control groups comprised of age- and sex-matched 10 healthy volunteers and 10 patients each of systemic lupus erythematosus and rheumatoid arthritis without any antecedent thrombotic event and/or APS-related pregnancy morbidity. Serum samples were tested for PAI-1 antigen levels measured by quantitative ELISA. Positivity rate of PAI-1 in patients of primary, secondary as well as total APS patients was significantly higher in relation to age- and sex-matched healthy volunteers (p = 0.010, p = 0.003 and p < 0.001, respectively). Mean ± SEM levels of PAI-1 in primary and secondary as well as total APS patients were significantly higher (p = 0.006, p < 0.001 and p < 0.001) in relation to healthy controls. Correlation of PAI-1 levels (mean ± SEM) with clinical characteristics, that is, thrombosis and pregnancy morbidity, revealed significantly higher levels of PAI-1 (p < 0.001) in patients having thrombosis and APS-related pregnancy morbidity. Elevated PAI-1 level leading to impaired fibrinolysis plays a significant role in producing hypercoagulable state in primary and secondary APS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311

    Article  PubMed  CAS  Google Scholar 

  2. Hughes GR (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088–1089

    Article  CAS  Google Scholar 

  3. Alarcon-Segovia D, Deleze M, Oria CV et al (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68:353–365

    CAS  Google Scholar 

  4. Arnold J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H (2001) Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage. Br J Haematol 113:911–914

    Article  PubMed  CAS  Google Scholar 

  5. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J et al (1997) Pregnancy loss in the antiphospholipid antibody syndrome—a possible thrombogenic mechanism. New Engl J Med 17:154–160

    Article  Google Scholar 

  6. Ruiz-Arguelles G, Ruiz-Arguelles A, Alarcon-Segovia D, Drenkar C, Villa A, Cabiedes J et al (1991) Natural anticoagulants in systemic lupus erythematosus: deficiency of protein S bound to C4 bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 18:552–558

    PubMed  CAS  Google Scholar 

  7. Cosgriff PM, Martin BA (1981) Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 24:94–96

    Article  PubMed  CAS  Google Scholar 

  8. Rand JH, Wu XX, Andree HA, Ross JB, Rusinova E, Gascon-Lema MG et al (1998) Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a lupus “procoagulant” phenomenon. Blood 92:165260

    Google Scholar 

  9. Arnout J, Vermylen J (1998) Mechanisms of action of β-2-glycoprotein I-dependent lupus anticoagulants. Lupus 7(suppl. 2):23–28

    Article  Google Scholar 

  10. Kornberg A, Renadineau Y, Blank M, Youinou P, Shoenfeld Y (2000) Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J 2(Suppl 2):27–31

    PubMed  Google Scholar 

  11. Carreras LO, de Freyn G, Machin SJ, Vermylen JG, Deman R, Spitz B et al (1981) Arterial thrombosis, intrauterine death and ‘lupus’ anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1:244–246

    Article  PubMed  CAS  Google Scholar 

  12. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J (1998) Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 79:42–45

    PubMed  CAS  Google Scholar 

  13. Urbanus RT, Derksen RH, de Groot PG (2008) Platelets and the antiphospholipid syndrome. Lupus 17:888

    Article  PubMed  CAS  Google Scholar 

  14. Zorio E, Gilabert-Estelles J, Espana F et al (2008) Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 15:923–929

    Article  PubMed  CAS  Google Scholar 

  15. Castellino FJ, Ploplis VA (2005) Structure and function of plasminogen/plasmin system. Thromb Haemost 93:647–654

    PubMed  CAS  Google Scholar 

  16. Huber K (2001) Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role of thromboembolic diseases. J Thromb Thrombolysis 11:183–193

    Article  PubMed  CAS  Google Scholar 

  17. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

    Article  PubMed  CAS  Google Scholar 

  18. Ames PR, Tommasino C, Iannaccone L et al (1996) Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies—a crucial role for acquired free protein S deficiency. Thromb Haemost 76:190–194

    PubMed  CAS  Google Scholar 

  19. Juardo M, Paramo JA, Gutierrez-Pimentel M, Rocha E (1992) Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 68:516–520

    Google Scholar 

  20. Coulam CB, Wallis D, Weinstein J, DasGupta DS, Jeyendran RS (2008) Comparison of thrombophilia gene mutations among patients experiencing recurrent miscarriages and deep vein thrombosis. Am J Reprod Immunol 60(5):426–431

    Article  PubMed  CAS  Google Scholar 

  21. Landin K, Tengborn L, Smith V (1990) Elevated fibrinogen and plasminogen activator (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273–278

    Article  PubMed  CAS  Google Scholar 

  22. Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen activator inhibitor levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457–462

    Article  PubMed  CAS  Google Scholar 

  23. Sobel BE, Woodcock-Mitchell J, Schneider DJ (1998) Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation 97:2213–2221

    Article  PubMed  CAS  Google Scholar 

  24. Hendrinks HFJ, Veenstgra J, Velthuis-teWierik EJM et al (1994) Effect of moderate dose of alcohol with evening meal on brinolytic factors. Br Med J 308:1003–1005

    Article  Google Scholar 

  25. Pralong G, Calandra T, Glauser MP et al (1989) Plasminogen activator inhibitor-1: a new prognostic marker in septic shock. Thromb Haemost 61:459–462

    PubMed  CAS  Google Scholar 

  26. Sartori MT, Winman B, Veltore S et al (1998) 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep venous thrombosis. Thromb Haemost 80:956–960

    PubMed  CAS  Google Scholar 

  27. Glueck CJ, Fontaine RN, Gupta A et al (1997) Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity and resistance to activated protein C. Metabolism 46:1470–1472

    Article  PubMed  CAS  Google Scholar 

  28. Margaglione M, Cappusi G, d’Addedda M et al (1998) PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environment and genetic determinants. Arterioscler Thromb Vasc Biol 18:562–567

    Article  PubMed  CAS  Google Scholar 

  29. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G (2008) The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 122:736–742

    Article  PubMed  CAS  Google Scholar 

  30. Yasuda S, Tsutsumi A, Atsumi T, Bertolaccini ML, Ichikawa K, Khamashta MA, Hughes GR, Koike T (2002) Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 29(6):1192–1197

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Our special thanks to Professor R. N. Mishra, Biostatistician for his kind help and suggestion.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, UP, India

    N. K. Singh

  2. Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, UP, India

    A. Gupta

  3. JR-3, General Medicine, Institute of Medical Sciences, Banaras Hindu University, Room No. 37, New PG Doctors Hostel, Varanasi, 221005, UP, India

    Dibya R. Behera

  4. Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, UP, India

    D. Dash

Authors
  1. N. K. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dibya R. Behera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Dash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dibya R. Behera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, N.K., Gupta, A., Behera, D.R. et al. Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome. Rheumatol Int 33, 2331–2336 (2013). https://doi.org/10.1007/s00296-013-2717-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-013-2717-0

Keywords

Search

Navigation